La catena delle opzioni mostra i dati chiave delle opzioni azionarie di 2seventy bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per 2seventy bio..

2seventy bio (NASDAQ:TSVT) Azioni, Catena delle Opzioni

2seventy bio

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Sanofi

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

TSVT

VRTX

L&#39;analisi sui settori più volatili e le strategie per affrontare le incertezze: ecco i trend da seguire per proteggere il tuo portafoglio.

3 titoli che potrebbero non farti dormire sonni tranquilli

2seventy bio Inc

Sysco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) reported <a href="https://www.benzinga.com/pressreleases/25/04/g45064242/sysco-reports-third-quarter-fiscal-year-2025-results">third-quarter FY25 sales</a> growth of 1.1% year-on-year to $19.60 billion, missing the analyst consensus estimate of $20.05 billion.
U.S. Foodservice operations sales rose 0.7% Y/Y, and International Foodservice sales slipped 1.1%.
Gross profit decreased 0.8% Y/Y to $3.6 billion, and the gross margin contracted 35 basis points to 18.3%.
The operating margin contracted 26 basis points to 3.5%, and operating income for the quarter declined 5.7% to $681 million. Non-GAAP operating margin declined 18 basis points to 3.9%.
Adjusted EBITDA decreased 0.8% Y/Y to $969 million in the quarter. Adjusted EPS of $0.96 <a href="https://www.benzinga.com/earnings">missed the consensus</a> estimate of $1.03.
Also Read: <a href="https://www.benzinga.com/movers-shakers/25/04/45066484/royal-caribbean-cruises-q1-benefits-from-strong-demand-stock-surges">Royal Caribbean Cruises&#8217; Q1 Benefits From Strong Demand, Stock Surges</a>
Sysco held $1.52 billion in cash and equivalents as of March 29. Operating cash flow for nine months totaled $1.3 billion, with a free cash flow of $954 million.
During the nine months, the company returned approximately $1.5 billion to shareholders through $700 million in share repurchases and $752 million in dividends.
"Sysco&#8217;s Q3 results were negatively impacted by multiple factors: California wildfires, significantly adverse weather, and more recently, weakening consumer confidence," said Kevin Hourican, Sysco's CEO.
&#8220;Each of these variables had a negative impact on foot traffic to restaurants which led the quarter, in total, to fall short of our internal expectations.&#8221;
Price Action: SYY shares traded lower by 0.18% at $70.24 on Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45040811/marriott-bets-355m-on-trendy-citizenm-hotels-to-woo-modern-travelers">Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers</a></li>
</ul>
Photo: Shutterstock

Earnings

Restaurants

Sysco Misses Q3 Targets As Wildfires, Declining Foot Traffic Weigh On Results

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) reported quarterly earnings of $7.81 per share which beat the analyst consensus estimate of $7.46 by 4.69 percent. This is a 27.2 percent increase over earnings of $6.14 per share from the same period last year. The company reported quarterly sales of $498.74 million which missed the analyst consensus estimate of $499.79 million by 0.21 percent. This is a 14.97 percent increase over sales of $433.81 million the same period last year.

Earnings Beats

Earnings Misses

FICO

Fair Isaac Q2 Adj. EPS $7.81 Beats $7.46 Estimate, Sales $498.74M Miss $499.79M Estimate

Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) raises FY2025 Adj EPS guidance from $0.52-$0.54 to $0.56-$0.58 vs $0.53 analyst estimate. Raises FY2025 sales outlook from $809.00 million-$821.00 million to $815.30 million-$824.30 million vs $813.28 million estimate.

Guidance

FRSH

Freshworks Raises FY2025 Adj EPS Guidance from $0.52-$0.54 to $0.56-$0.58 vs $0.53 Est; Raises FY2025 Sales Guidance from $809.00M-$821.00M to $815.30M-$824.30M vs $813.28M Est

Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) is looking for Q2 Adj EPS of $0.10-$0.12 vs $0.11 analyst estimate. sees sales of $197.300 million-$200.300 million vs $197.98 million analyst estimate.

Freshworks Sees Q2 Adj EPS $0.10-$0.12 vs $0.11 Est; Sees Sales $197.300M-$200.300M vs $197.98M Est

Extra Space Storage Q1 FFO $2.00 Beats $1.98 Estimate, Property Rental Revenue $704.38M Miss $763.47M Estimate

Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) reported quarterly earnings of $24.81 per share which beat the analyst consensus estimate of $17.30 by 43.41 percent. This is a 21.68 percent increase over earnings of $20.39 per share from the same period last year. The company reported quarterly sales of $4.76 billion which beat the analyst consensus estimate of $4.59 billion by 3.83 percent. This is a 7.86 percent increase over sales of $4.42 billion the same period last year.

BKNG

Booking Holdings Q1 Adj. EPS $24.81 Beats $17.30 Estimate, Sales $4.76B Beat $4.59B Estimate

BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) is looking for Q2 FFO of $1.65-$1.67 vs $1.69 analyst estimate..

BXP Sees Q2 FFO $1.65-$1.67 vs $1.69 Est

BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) narrows FY2025 FFO guidance from $6.77-$6.95 to $6.80-$6.92 vs $6.88 analyst estimate..

BXP Narrows FY2025 FFO Guidance from $6.77-$6.95 to $6.80-$6.92 vs $6.88 Est

On April 23, 2025, Artelo Biosciences, Inc. (the "Company") received written notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 20, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, subject to Nasdaq's discretion, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.

ARTL

Artelo Biosciences Receives Nasdaq Non-Compliance Notice

Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.13 by 38.46 percent. This is a 80 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $196.27 million which beat the analyst consensus estimate of $191.86 million by 2.30 percent. This is a 18.85 percent increase over sales of $165.14 million the same period last year.

Freshworks Q1 Adj. EPS $0.18 Beats $0.13 Estimate, Sales $196.27M Beat $191.86M Estimate

Ribbon Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) affirms FY2025 sales outlook from $870.00 million-$890.00 million to $870.00 million-$890.00 million vs $880.86 million estimate.

RBBN

Ribbon Communications Affirms FY2025 Sales Guidance of $870.00M-$890.00M vs $880.86M Est

Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.49 by 2.01 percent. This is a 16.92 percent increase over earnings of $1.30 per share from the same period last year. The company reported quarterly sales of $1.17 billion which met the analyst consensus estimate. This is a 16.14 percent increase over sales of $1.01 billion the same period last year.

ENSG

Ensign Group Q1 Adj. EPS $1.52 Beats $1.49 Estimate, Sales $1.17B Inline

Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) raises FY2025 sales outlook from $2.32 billion-$2.35 billion to $2.37 billion-$2.38 billion vs $2.34 billion estimate.

Stride Raises FY2025 Sales Guidance from $2.32B-$2.35B to $2.37B-$2.38B vs $2.34B Est

ACGL

Arch Capital Group Q1 Adj. EPS $1.54 Beats $1.32 Estimate, Sales $4.19B Miss $4.71B Estimate

Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.81 by 2.47 percent. This is a 6.74 percent decrease over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $200.38 million which missed the analyst consensus estimate of $202.97 million by 1.27 percent. This is a 5.16 percent decrease over sales of $211.28 million the same period last year.

Highwoods Props Q1 FFO $0.83 Beats $0.81 Estimate, Sales $200.38M Miss $202.97M Estimate

Boston Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) reported quarterly earnings of $1.64 per share which missed the analyst consensus estimate of $1.65 by 0.61 percent. This is a 5.2 percent decrease over earnings of $1.73 per share from the same period last year. The company reported quarterly sales of $865.22 million which beat the analyst consensus estimate of $841.89 million by 2.77 percent. This is a 3.07 percent increase over sales of $839.44 million the same period last year.

Boston Props Q1 FFO $1.64 Misses $1.65 Estimate, Sales $865.22M Beat $841.89M Estimate

Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) reported quarterly earnings of $0.12 per share which met the analyst consensus estimate. This is a 14.29 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $712.11 million which missed the analyst consensus estimate of $738.62 million by 3.59 percent. This is a 7.41 percent decrease over sales of $769.08 million the same period last year.

WERN

Werner Enterprises Q1 Adj. EPS $0.12, Inline, Sales $712.11M Miss $738.62M Estimate

ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) reported quarterly earnings of $1.04 per share which missed the analyst consensus estimate of $1.23 by 15.45 percent. This is a 4.59 percent decrease over earnings of $1.09 per share from the same period last year.

ONEOK Q1 EPS $1.04 Misses $1.23 Estimate

Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 57.89 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $1.36 billion which beat the analyst consensus estimate of $1.35 billion by 1.29 percent. This is a 14.06 percent increase over sales of $1.20 billion the same period last year.

SNAP

Snap Q1 EPS $(0.08) Beats $(0.13) Estimate, Sales $1.36B Beat $1.35B Estimate

Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $2.00 by 1 percent. This is a 26.25 percent increase over earnings of $1.60 per share from the same period last year. The company reported quarterly sales of $613.38 million which beat the analyst consensus estimate of $591.07 million by 3.77 percent. This is a 17.77 percent increase over sales of $520.84 million the same period last year.

Stride Q3 EPS $2.02 Beats $2.00 Estimate, Sales $613.38M Beat $591.07M Estimate

Press Releases

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TSVT, BRDG, GB on Behalf of Shareholders

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

Comments

2seventy bio

2seventy bio (TSVT) Opzioni

2seventy bio (NASDAQ:TSVT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO